Diagnostics company Quanterix Corporation (NASDAQ: QTRX) announced on Monday that it is collaborating with health networks AdventHealth, Mass General Brigham, Mayo Clinic, MUSC and UPMC to enhance Alzheimer's disease (AD) diagnosis and clinical management.

These partnerships leverage Quanterix's ultra-sensitive technology, offering high-accuracy, non-invasive AD testing. With a combined reach of 140+ hospitals across 18 states, impacting 21 million patients, the initiative aims to make blood-based biomarker testing more accessible, replacing traditional invasive methods.

The company's commitment to industry-standard accuracy positions it as a crucial partner in AD testing globally. The Simoa p-Tau 217 assays align with NIA-AA criteria for AD diagnosis.

Quanterix, a provider of ultrasensitive biomarker detection, provides breakthroughs in neurology, oncology, immunology, cardiology and infectious disease. Simoa technology sets the gold standard for earlier biomarker detection, supporting research published in over 2,700 peer-reviewed journals.

Lucent Diagnostics, a Quanterix brand, focuses on transforming AD diagnostic testing. LucentAD, powered by Simoa, simplifies AD assessment for healthcare providers, measuring top-performing biomarkers p-Tau 181 and p-Tau 217 in plasma. The initiative addresses the critical need for advanced diagnostic tools in neurodegenerative diseases.